Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an intravenous solution for intravenous use. It selectively dilates cerebral arteries and is employed to prevent cerebral vasospasm following subarachnoid hemorrhage in adult patients at risk of neurological complications.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, with regulatory approvals across the European Union and other major markets. The company adheres to WHO‑GMP standards and provides temperature‑controlled logistics where required.

Nimodipine is used to address cerebral vasospasm, a vascular complication that can follow subarachnoid hemorrhage. - Subarachnoid hemorrhage (SAH) prophylaxis: prevents delayed cerebral vasospasm after aneurysmal bleed. - Aneurysmal SAH management: supports maintenance of cerebral perfusion during the vasospasm risk period. - Neurosurgical postoperative care: reduces incidence of vasospasm‑related ischemia in patients undergoing clipping or coiling.

Nimotop may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: transient drop in blood pressure. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: warmth and redness of skin. - Dizziness: sensation of light‑headedness. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Myocardial infarction: rare cardiac event. - Hepatic dysfunction: abnormal liver enzymes. - Anaphylactic reaction: signs of severe allergy. - Thrombocytopenia: low platelet count. - Seizures: uncommon neurologic event.

When using Nimotop, clinicians should consider several safety measures. - Renal impairment: monitor fluid balance and renal function. - Hepatic impairment: use with caution and observe liver enzymes. - Concomitant antihypertensives: may potentiate hypotensive effect. - Pregnancy: safety not established; weigh benefits against potential risks. - Elderly patients: increased sensitivity to blood‑pressure changes. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nimodipine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use with other potent vasodilators: risk of severe hypotension. - Combination with beta‑blockers: may cause bradycardia and profound hypotension. - Use with strong CYP3A4 inhibitors (e.g., ketoconazole): increased plasma concentrations. - Use with CYP3A4 inducers (e.g., rifampicin): reduced therapeutic effect.

Moderate Interactions (Monitor Closely): - Co‑administration with diuretics: may affect electrolyte balance. - Concurrent use with other calcium channel blockers: additive cardiovascular effects.